TREVI HEALTH VENTURES

News

portfolioLogo

  1. August 10, 2010

    Omeros Reports Second Quarter 2010 Financial Results

  2. August 5, 2010

    Omeros to Webcast Presentation at Canaccord Genuity 30th Annual Growth Conference

  3. July 27, 2010

    Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery

  4. June 29, 2010

    Omeros Successfully Unlocks Orphan GPCRs

  5. June 29, 2010

    Omeros Secures $40 Million Committed Equity Financing Facility

  6. June 3, 2010

    Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference

  7. May 13, 2010

    Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders

  8. May 12, 2010

    Omeros Reports First Quarter 2010 Financial Results

  9. May 3, 2010

    Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery

  10. April 29, 2010

    Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference

  11. March 31, 2010

    Omeros Corporation Reports Fourth Quarter and Year-End 2009 Financial Results

  12. March 31, 2010

    Omeros Reports Phase 2 Data Showing Multiple Clinical Benefits in Patients Undergoing Arthroscopic Meniscectomy Surgery

  13. March 15, 2010

    Omeros Corporation to Host Conference Call on Fourth Quarter and Full Year 2009 Results on March 31

  14. March 9, 2010

    Omeros Licenses PDE7 Compounds for Parkinson's Disease Program

  15. January 28, 2010

    Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program

  16. December 9, 2009

    Daniel K. Spiegelman Elected to Board of Directors of Omeros

  17. November 19, 2009

    Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights

  18. November 13, 2009

    Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19

  19. October 7, 2009

    Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share

  20. September 17, 2009

    Omeros and The Parkinson's Institute Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders

  21. August 11, 2009

    Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmological Surgery

  22. August 5, 2009

    Omeros Appoints New Vice President of Clinical Development

  23. January 28, 2009

    Omeros Awarded $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program

  24. January 6, 2009

    Omeros Awarded Grant from The Michael J. Fox Foundation

  25. December 9, 2008

    Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery

  26. September 24, 2008

    Omeros and BlueCrest Announce $20 Million Debt Facility

  27. September 9, 2008

    Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302

  28. August 26, 2008

    Omeros Announces Publication of Clinical Results of OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery

  29. August 19, 2008

    Affitech and Omeros Enter into Antibody Discovery and Development Agreement

  30. May 20, 2008

    Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study

  31. February 12, 2007

    Omeros Raises More Than $63 Million in Financing

  32. January 9, 2007

    Omeros Receives up to $9 Million Toward Development of Schizophrenia Treatment